BVAXF (BioVaxys Technology) LT-Debt-to-Total-Asset : 0.00 (As of Oct. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. BioVaxys Technology's long-term debt to total assests ratio for the quarter that ended in Oct. 2024 was 0.00.

BioVaxys Technology's long-term debt to total assets ratio stayed the same from Oct. 2023 (0.00) to Oct. 2024 (0.00).

BioVaxys Technology LT-Debt-to-Total-Asset Historical Data

The historical data trend for BioVaxys Technology's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioVaxys Technology LT-Debt-to-Total-Asset Chart

BioVaxys Technology Annual Data

Trend

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Oct24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

BioVaxys Technology Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

BioVaxys Technology LT-Debt-to-Total-Asset Calculation

BioVaxys Technology's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (A: Oct. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Oct. 2024 )	/	Total Assets (A: Oct. 2024 )
	=	0	/	0.946
	=

BioVaxys Technology's Long-Term Debt to Total Asset Ratio for the quarter that ended in Oct. 2024 is calculated as

LT Debt to Total Assets (Q: Oct. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Oct. 2024 )	/	Total Assets (Q: Oct. 2024 )
	=	0	/	0.946
	=

BioVaxys Technology (OTCPK:BVAXF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

BioVaxys Technology LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of BioVaxys Technology's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BioVaxys Technology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

5LB:Germany BIOV:Canada

Address

146 Thirtieth Street, Suite 100, Etobicoke, ON, CAN, M8W 3D4

Website

https://www.biovaxys.com

BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.